Paolo Tarantino: Rational KRAS inhibitor combinations by Sandra Misale at ENA Symp 24
Paolo Tarantino, Research Fellowship Scholar at Dana-Farber Cancer Institute, shared a post on X:
“Terrific talk on rational KRAS inhibitor combinations by Sandra Misale at ENA Symp 24.
Tackling multiple molecular vulnerabilities is critical to achieve satisfying clinical activity in the context of molecularly complex tumors.
Including with ADC combinations.”
Dr. Paolo Tarantino, MD, is pursuing an advanced research fellowship at Dana-Farber Cancer Institute and Harvard Medical School, concurrently working towards a PhD in clinical research at the University of Milan. His research focuses on exploring the HER2 oncoprotein, investigating the emerging HER2-low subgroup of breast tumors, and developing novel antibody-drug conjugates targeting every subtype of breast cancer. With a publication record exceeding 50 papers on breast cancer, he is recognized as a leading expert in the field.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023